Evogene (TSE:EVGN – Free Report) had its target price cut by Ventum Financial from C$4.00 to C$3.00 in a report published on Friday,BayStreet.CA reports.
Evogene Price Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Further Reading
- Five stocks we like better than Evogene
- About the Markup Calculator
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Energy and Oil Stocks Explained
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
